MediciNova Inc (NASDAQ:MNOV)

4.09
Delayed Data
As of Apr 24
 +0.11 / +2.76%
Today’s Change
1.72
Today|||52-Week Range
5.90
+34.54%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$100.7M

Company Description

MediciNova, Inc. operates as a biopharmaceutical company with interest in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. The company's development pipeline consists of product development programs which have been in clinical development for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorder, preterm labor and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in San Diego, CA.

Contact Information

MediciNova, Inc.
4275 Executive Square
La Jolla California 92037
P:(858) 373-1500
Investor Relations:

Employees

Shareholders

Mutual fund holders3.26%
Other institutional2.24%
Individual stakeholders15.10%

Top Executives

Yuichi IwakiPresident, Chief Executive Officer & Director
Esther van den BoomChief Financial & Accounting Officer
Kazuko MatsudaChief Medical Officer
Masatsune OkajimaVice President & Head-Japanese Office
Geoffrey G. O'BrienVice President & Head-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account